# BPC-157: Research Overview — Winning Edge Peptides > A literature summary of BPC-157 (Body Protection Compound 157), the lead Recovery & Tissue Repair research peptide on this desk: angiogenesis mechanism, rodent healing studies, pharmacokinetics, and regulatory status. Body Protection Compound 157 — a stable gastric pentadecapeptide whose repair effects in animal models track most closely with the growth of new blood vessels. ## The short version BPC-157 stands for **Body Protection Compound 157**. It is a synthetic peptide fifteen amino acids long, copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to accelerate healing in several tissue types: tendons, the gut lining, and nerve [5][6]. The most consistent explanation researchers give is that it helps the body grow new blood vessels into an injury, bringing the oxygen and nutrients that repair requires [4]. Here is the honest part. Almost all of this evidence is in animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous human trials [2]. BPC-157 is not an approved drug anywhere, it is banned in sport, and popular claims about weight loss or muscle building are not supported by the published science [2]. This page summarizes what was studied; it is not advice and lists no human dose. ## What it is BPC-157 is a *stable gastric pentadecapeptide* — "pentadecapeptide" means a fifteen-amino-acid peptide, and "stable gastric" because the sequence comes from a cytoprotective protein in gastric juice and resists breakdown in the stomach. Its amino-acid sequence is `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`, and it is catalogued under research designations such as PL 14736, PLD-116, and PL-10. It is a synthetic research peptide, not a natural extract, and not an approved drug. Its molecular formula is C62H98N16O22. ## How it works The best-characterized mechanism is *angiogenesis* — the formation of new blood vessels. In a 2017 study spanning a chick-membrane model, a rat hindlimb ischemia model, and human endothelial cells, BPC-157 increased the expression of a key vessel-growth receptor called VEGFR2 and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect [4]. In plain terms: it appears to make blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model. Beyond vessels, BPC-157 is described as a *brain-gut-axis* mediator that modulates serotonin and dopamine systems and engages cell-migration pathways such as FAK-paxillin, along with Egr-1/NAB2 and JAK-2 signaling [7]. Reported routes also include sensitizing the growth-hormone receptor in tendon fibroblasts. The throughline is a peptide that nudges several repair-related signals at once rather than hitting a single target. ## What the research shows *Foundational cytoprotection.* The compound's name traces to its gut origins. In Wistar rats, BPC-157 reduced gastric-ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric, and ulcer-formation inhibition ratios of roughly 46-66% at higher doses [5]. *Tendon.* In a fully transected rat Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures and stimulated tendon-cell (tendocyte) outgrowth in culture, with better collagen organization and restored tendon integrity versus untreated controls [6]. *Pharmacokinetics.* The first formal PK/ADME work, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism [3]. A short half-life means the intact peptide does not linger in the bloodstream. *Human evidence.* It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers — but the sample was two people, and it was a safety pilot, not an efficacy trial [1]. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational [2]. ## Reported effects, cautions & safety The safety picture inside the tiny human dataset and the animal work is reassuring as far as it goes — but "as far as it goes" is the operative phrase. The absence of long-term, large-sample human safety data means the real-world safety profile is genuinely unknown [2]. Several cautions follow directly from the literature: - *Evidence is overwhelmingly preclinical.* Most of what is reported comes from rodents, and a large share of the foundational work originates from a single research group, which newer authors explicitly flag as raising independent-replication questions [2]. - *Unregulated supply.* BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, so product identity, purity and dose are unverified outside formal studies. - *Banned in sport.* It is prohibited at all times by the World Anti-Doping Agency under the S0 (non-approved substances) category — a direct concern for any competitive athlete. - *Unsupported claims.* Common online claims such as weight loss, muscle building, or raising testosterone are not supported by the published evidence and should be treated skeptically [2]. No community-anecdote signals are compiled in this desk's source material for BPC-157, so none are presented here; the cautions above are drawn from the cited literature. ## Where it fits in recovery research Among the three peptides on this desk, BPC-157 is the lead and the most broadly studied — but breadth is not the same as depth. Its animal record spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward story, while its human file remains three small pilots [2]. Read alongside [TB-500](/tb-500), which approaches repair through cell migration, and [GHK-Cu](/ghk-cu), which carries the strongest human (topical) data, BPC-157 illustrates the central tension of this whole field: a coherent, decades-deep preclinical signal that has barely crossed into controlled human work. See the [comparison page](/compare) for how it lines up. ![BPC-157 research illustration showing filament networks and healing matrices in cold cyan graphite](/images/bpc-157.webp) --- Peer-reviewed findings, reported straight — no prescriptions, no products, no dose recommendations.